Emcure Pharmaceuticals Limited — Important, 21-06-2025: Updates

Emcure has announced a board meeting on the financial results for the quarter and half-year. Key performance highlights for FY25 include 46.3% of revenue from India and 53.7% from overseas markets. EBITDA rose to ₹1,531.3 Cr with a stable margin around 19.2%. Profit after tax reached ₹707.5 Cr, improving margin to 8.9%. Return on Capital Employed improved to 22%, indicating efficient capital use. The business shows steady growth in operational profitability and expanding global contribution.